163 related articles for article (PubMed ID: 35861307)
1. Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma.
Acharya N; Singh KP
WIREs Mech Dis; 2022 Nov; 14(6):e1575. PubMed ID: 35861307
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in renal cell cancer: mechanisms and clinical applications.
Joosten SC; Smits KM; Aarts MJ; Melotte V; Koch A; Tjan-Heijnen VC; van Engeland M
Nat Rev Urol; 2018 Jul; 15(7):430-451. PubMed ID: 29867106
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer.
Roy P; Singh KP
Int Rev Cell Mol Biol; 2023; 380():173-210. PubMed ID: 37657858
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic background.
Acharya N; Singh KP
Mol Cell Biochem; 2021 Jun; 476(6):2365-2379. PubMed ID: 33591455
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions.
Goldsamt A; Damayanti NP; De Nigris F; Pili R
Cancer J; 2020; 26(5):399-406. PubMed ID: 32947308
[TBL] [Abstract][Full Text] [Related]
6. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in advanced renal cell carcinoma: Potential new targets.
Molina-Cerrillo J; Santoni M; Ruiz Á; Massari F; Pozas J; Ortego I; Gómez V; Grande E; Alonso-Gordoa T
Crit Rev Oncol Hematol; 2022 Dec; 180():103857. PubMed ID: 36257538
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
Galle E; Thienpont B; Cappuyns S; Venken T; Busschaert P; Van Haele M; Van Cutsem E; Roskams T; van Pelt J; Verslype C; Dekervel J; Lambrechts D
Clin Epigenetics; 2020 Feb; 12(1):27. PubMed ID: 32059745
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.
Piva F; Giulietti M; Santoni M; Occhipinti G; Scarpelli M; Lopez-Beltran A; Cheng L; Principato G; Montironi R
Mol Diagn Ther; 2016 Apr; 20(2):111-7. PubMed ID: 26940073
[TBL] [Abstract][Full Text] [Related]
10. Genomics and epigenomics of renal cell carcinoma.
Maher ER
Semin Cancer Biol; 2013 Feb; 23(1):10-7. PubMed ID: 22750267
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
12. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
13. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
14. Chronic Oxidative Stress Increases Resistance to Doxorubicin-Induced Cytotoxicity in Renal Carcinoma Cells Potentially Through Epigenetic Mechanism.
Ponnusamy L; Mahalingaiah PK; Singh KP
Mol Pharmacol; 2016 Jan; 89(1):27-41. PubMed ID: 26519223
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
16. Arsenic induces fibrogenic changes in human kidney epithelial cells potentially through epigenetic alterations in DNA methylation.
Chang YW; Singh KP
J Cell Physiol; 2019 Apr; 234(4):4713-4725. PubMed ID: 30191986
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.
Li H; Wang J; Xiao W; Xia D; Lang B; Yu G; Guo X; Guan W; Wang Z; Hu Z; Liu J; Ye Z; Xu H
Carcinogenesis; 2013 Oct; 34(10):2262-70. PubMed ID: 23722653
[TBL] [Abstract][Full Text] [Related]
18. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
19. Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells.
Kubo Y; Tanaka K; Masuike Y; Takahashi T; Yamashita K; Makino T; Saito T; Yamamoto K; Tsujimoto T; Harino T; Kurokawa Y; Yamasaki M; Nakajima K; Eguchi H; Doki Y
J Transl Med; 2022 Aug; 20(1):383. PubMed ID: 36038893
[TBL] [Abstract][Full Text] [Related]
20. Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis.
Lichner Z; Mac-Way F; Yousef GM
Eur Urol Focus; 2019 Mar; 5(2):250-261. PubMed ID: 28847686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
